Perfect Storm for $VRX to TankFirst we have the WF analyst report, now CVS cutting coverage for fungal drug Jublia, then the report of a restatement of earnings based on internal investigations. Who's gonna pile on next, Citron again?
Despite this, guess what? CXR's story hasn't changed a bit throughout all this. Any drop in association with VRX's issues is unjustified and will rebound in due time. Now's time to ride out the storm. RBC presentation on Wednesday and Q4 earnings approaching.